Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised Phase II Trial of Sorafenib, Capecitabine and Oxaliplatin (SECOX) Versus Single Agent Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Trial Profile

Randomised Phase II Trial of Sorafenib, Capecitabine and Oxaliplatin (SECOX) Versus Single Agent Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2019

At a glance

  • Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Jan 2019 Primary endpoint has not been met. (Time-to-progression (TTP)), as reported in an abstract presented at the 2019 Gastrointestinal Cancers Symposium
    • 19 Jan 2019 Results presented at the 2019 Gastrointestinal Cancers Symposium
    • 02 Sep 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top